Posttranslational Modification Cross-Talk in Vascular Cells: Molecular Mechanisms and Therapeutic Implications for Atherosclerosis.
- 1Department of Cardiovascular Medicine, The 970th Hospital of the Joint Logistic Support Force of the People's Liberation Army, Yantai, China.
- 2Department of Cardiology, Yantaishan Hospital, Yantai, Shandong, China.
Abstract
Atherosclerosis is driven by coordinated changes in endothelial cells (ECs), macrophages, and vascular smooth muscle cells (VSMCs). Post-translational modifications (PTMs), phosphorylation, acetylation, ubiquitination, SUMOylation, O-GlcNAcylation, palmitoylation, ISGylation, and ADP-ribosylation, integrate metabolic, inflammatory, and mechanical inputs at a limited number of signaling nodes. This review argues that these modifications interact according to four definable relationships rather than merely co-occurring. In competitive cross-talk, two marks contest one acceptor residue, as when O-GlcNAcylation displaces phosphorylation at the Akt site of endothelial nitric oxide synthase. In hierarchical cross-talk, one modification licenses another, as when Ser536 phosphorylation of NF-κB p65 recruits p300 and permits Lys310 acetylation. In enzyme-directed cross-talk, a modification acts on the writer or eraser of a different system, as HDAC9 does on IκB kinases. In cofactor-coupled cross-talk, sirtuin-dependent deacylation and PARP1-dependent ADP-ribosylation draw on one limiting NAD⁺ pool. We rank nodes against four stated criteria, grade every finding on a five-level evidence scheme, and apply the framework to phosphorylation-O-GlcNAcylation, ubiquitination-SUMOylation, and acetylation-ubiquitination interactions across the three vascular cell types. Of the cross-talk relationships invoked, five are supported at residue resolution by a substitution experiment, and two of these were obtained in vascular cells; the remainder are inferred from enzyme-level regulation or from pathway convergence. Candidate intervention points include HDAC9, SENP3, OGT, UBA1, and the NAD⁺ pool, none of which has been evaluated in a cardiovascular outcome trial.
Related
- Transendothelial Transport of Low-Density Lipoproteins in Atherosclerosis: Mechanisms of Activation and Possible Therapeutic Targets
- Role of insulin resistance in atherosclerosis: underlying mechanisms and emerging stem cell-based therapeutic strategies.
- Selenium Nanoparticles in Atherosclerosis and Non-Alcoholic Fatty Liver Disease: A Comprehensive Review of Therapeutic Mechanisms, Targeted Delivery, and Translational Prospects
- Gut Microbiota-Driven Neuroimmune Crosstalk in Ulcerative Colitis: From Mechanisms to Therapeutic Implications
- Exerkines in Cardiovascular–Kidney–Metabolic Syndrome: An Integrative Framework for Mechanisms and Therapeutic Implications—A Narrative Review
BibTeX
@article{jiang2026posttranslational,
title = {{Posttranslational Modification Cross-Talk in Vascular Cells: Molecular Mechanisms and Therapeutic Implications for Atherosclerosis.}},
author = {Weiwei Jiang and Haiping Du},
journal = {Cell biochemistry and function},
year = {2026},
month = nov,
doi = {10.1002/cbf.70329},
url = {https://europepmc.org/article/MED/42968629},
note = {CC BY},
}
RIS
TY - JOUR
TI - Posttranslational Modification Cross-Talk in Vascular Cells: Molecular Mechanisms and Therapeutic Implications for Atherosclerosis.
AU - Weiwei Jiang
AU - Haiping Du
PY - 2026
DA - 2026/11/01
JO - Cell biochemistry and function
DO - 10.1002/cbf.70329
UR - https://europepmc.org/article/MED/42968629
AB - Atherosclerosis is driven by coordinated changes in endothelial cells (ECs), macrophages, and vascular smooth muscle cells (VSMCs). Post-translational modifications (PTMs), phosphorylation, acetylation, ubiquitination, SUMOylation, O-GlcNAcylation, palmitoylation, ISGylation, and ADP-ribosylation, integrate metabolic, inflammatory, and mechanical inputs at a limited number of signaling nodes. This review argues that these modifications interact according to four definable relationships rather than merely co-occurring. In competitive cross-talk, two marks contest one acceptor residue, as when O-GlcNAcylation displaces phosphorylation at the Akt site of endothelial nitric oxide synthase. In hierarchical cross-talk, one modification licenses another, as when Ser536 phosphorylation of NF-κB p65 recruits p300 and permits Lys310 acetylation. In enzyme-directed cross-talk, a modification acts on the writer or eraser of a different system, as HDAC9 does on IκB kinases. In cofactor-coupled cross-talk, sirtuin-dependent deacylation and PARP1-dependent ADP-ribosylation draw on one limiting NAD⁺ pool. We rank nodes against four stated criteria, grade every finding on a five-level evidence scheme, and apply the framework to phosphorylation-O-GlcNAcylation, ubiquitination-SUMOylation, and acetylation-ubiquitination interactions across the three vascular cell types. Of the cross-talk relationships invoked, five are supported at residue resolution by a substitution experiment, and two of these were obtained in vascular cells; the remainder are inferred from enzyme-level regulation or from pathway convergence. Candidate intervention points include HDAC9, SENP3, OGT, UBA1, and the NAD⁺ pool, none of which has been evaluated in a cardiovascular outcome trial.
SN - 0263-6484
SN - 1099-0844
ER -